Cohort 1 enrolment achieved for TRP-8803 BED Trial
Filed with ASX · · 3 pages · English
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Australian Patent Secures TRP 8803 Platform to 2042
- Quarterly Activities Report and Appendix 4C
- First TRP-8803 BED patient shows broad clinical improvement
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
Later from Entropy Neurodynamics
- FY25 R&D Tax Incentive received
- TRP-8803 delivers repeatable, high-intensity effect
- TRP 8802 delivers 75% breakthrough response in IBS
- Entropy files new US patent for IBS program
- Entropy completes Cohort 1 dosing in BED trial
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics